Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Report 2026

The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market size has grown strongly in recent years. It will grow from $2.89 billion in 2025 to $3.1 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to limited number of specialized peptide api manufacturers, growing demand for peptide therapeutics, reliance on in-house synthesis by pharma companies, regulatory compliance requirements, increasing preclinical and clinical trials.

The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market size is expected to see strong growth in the next few years. It will grow to $4.11 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to expansion of cmo capabilities for peptide api, rising investment in advanced peptide synthesis technologies, growth of personalized medicine and biologics, increasing outsourcing by small and mid-size pharma companies, adoption of digital manufacturing and ai-based process optimization. Major trends in the forecast period include rising demand for contract manufacturing of peptide apis, increased focus on gmp-grade production and compliance, growth in outsourced peptide synthesis for clinical trials, expansion of process optimization and tech transfer services, adoption of custom peptide synthesis for personalized therapeutics.

The rising prevalence of diabetes is expected to drive growth in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market in the coming years. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels caused by insufficient insulin production or the body’s inability to use insulin effectively. The increasing prevalence of diabetes is largely driven by rising obesity rates, as excess body fat contributes to insulin resistance and impairs blood sugar regulation. Peptide therapeutics rely on contract API manufacturing to enable large-scale production of hormone-mimicking drugs, which enhance insulin secretion and help control glucose levels in diabetes management. For instance, in March 2025, the Office for Health Improvement and Disparities reported that type 2 diabetes prevalence among adults aged 17 and older in England reached 7% in March 2024, up from 6.8% in March 2023. Therefore, the growing prevalence of diabetes is boosting the peptide therapeutics contract API manufacturing market.

Key companies in this market are focusing on innovative solutions such as continuous flow synthesis platforms to streamline production and manage the increasing complexity of drug development. Continuous flow synthesis integrates reaction, separation, concentration, and crystallization into a single uninterrupted process with real-time in-line monitoring, enabling precise, scalable, and efficient manufacturing. For example, in May 2023, SynCrest Inc., a Japan-based CRDMO, launched its GMP-compliant Naruto Plant equipped with a continuous flow synthesis platform for peptide and nucleotide API production. This platform allows rapid manufacturing of over 100 types of non-natural amino acids and high-purity special amidites, reducing lead times and production costs.

In December 2024, Novo Holdings A/S, a Denmark-based asset management company, acquired Catalent Inc. for $16.5 billion. This acquisition aims to optimize the development and delivery of transformative therapies, enhance global patient outcomes, and create sustainable value in life sciences. Catalent Inc., a US-based pharmaceutical company, provides contract manufacturing services for APIs, including peptide therapeutics APIs.

Major companies operating in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market are Thermo Fisher Scientific Inc., Lonza Group AG., WuXi AppTec Co. Ltd., Cambrex Corporation, ChemPartner, GenScript Biotech Corporation, Bachem Group, CordenPharma International GmbH, Syngene International Limited, Ambiopharm Inc., CPC Scientific Inc., ScinoPharm Taiwan Ltd., Hybio Pharmaceutical Co. Ltd., CSBio Company Inc., Senn Chemicals AG., AnaSpec Inc., LifeTein LLC, Apex Biotechnology Corp., BCN Peptides S.A.

North America was the largest region in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the peptide therapeutics contract API manufacturing market by increasing the cost of imported raw materials, reagents, and specialized synthesis equipment. Commercial-scale manufacturing and tech transfer segments are most affected, particularly in regions such as North America and Europe that rely heavily on imports. This has led to higher production costs and potential delays in clinical and commercial supply. On the positive side, tariffs are encouraging local production, investment in domestic synthesis capabilities, and innovation in process optimization, which may reduce long-term dependency on imports.

The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market research report is one of a series of new reports that provides peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market statistics, including peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing industry global market size, regional shares, competitors with a peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market share, detailed peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing industry. This peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing refers to the outsourced production of peptide-based APIs by specialized third-party manufacturers operating under strict regulatory compliance. These manufacturers provide services such as custom synthesis, purification, and good manufacturing practice (GMP)-grade production to support both clinical trials and commercial supply of peptide therapeutics.

The main scales of operation in peptide therapeutics contract API manufacturing include preclinical or clinical stages and commercial production. The preclinical or clinical stage encompasses early drug development, including laboratory research and human trials to assess the safety and efficacy of peptide drugs. Different synthesis methods, such as chemical and non-chemical synthesis, are employed to meet the needs of various enterprise types, including large enterprises as well as small and medium-sized enterprises.

The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market includes revenues earned by entities through custom peptide synthesis, process development and optimization, and analytical development and quality control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.